TP63 Gene: A Promising Drug Target Or Biomarker (G8626)

Target Name: TP63

NCBI ID: G8626

TP63

TP63 Gene: A Promising Drug Target Or Biomarker

TP63 (Tumor suppressor gene 63) is a gene that has been identified as a potential drug target or biomarker for various diseases, including cancer. It is a transmembrane gene that is located on chromosome 1p36 and has been shown to play a role in the development and progression of various diseases.

The TP63 gene is composed of 25 exons that encode a protein known as TP63. This protein is involved in a variety of cellular processes, including cell growth, apoptosis (programmed cell death), and inflammation. It is also known for its role in the development and progression of cancer, as well as its potential as a drug target.

One of the most promising aspects of the TP63 gene is its potential as a drug target. The TP63 gene has been shown to be involved in the development and progression of a variety of diseases, including cancer, neurodegenerative diseases, and autoimmune disorders. It is also known to be involved in the regulation of cellular processes that are important for the development and maintenance of cancer, such as cell growth, apoptosis, and inflammation.

In addition to its potential as a drug target, the TP63 gene is also being investigated as a biomarker for various diseases. Its expression has been shown to be elevated in a variety of diseases, including cancer, and it has been used as a biomarker for disease diagnosis and monitoring in a number of studies.

The TP63 gene is also of interest to researchers because of its location on chromosome 1p36. This gene is located near the critical region of the X chromosome, which is known for its role in the development and progression of certain diseases. The fact that the TP63 gene is located in this region has led some researchers to speculate that it may be a candidate for therapies that target the X chromosome.

In conclusion, the TP63 gene is a promising candidate as a drug target or biomarker for a variety of diseases. Its location on chromosome 1p36 and its involvement in the development and progression of cancer make it an attractive target for researchers to investigate further. Further studies are needed to fully understand the potential of the TP63 gene as a drug and biomarker.

Protein Name: Tumor Protein P63

Functions: Acts as a sequence specific DNA binding transcriptional activator or repressor. The isoforms contain a varying set of transactivation and auto-regulating transactivation inhibiting domains thus showing an isoform specific activity. Isoform 2 activates RIPK4 transcription. May be required in conjunction with TP73/p73 for initiation of p53/TP53 dependent apoptosis in response to genotoxic insults and the presence of activated oncogenes. Involved in Notch signaling by probably inducing JAG1 and JAG2. Plays a role in the regulation of epithelial morphogenesis. The ratio of DeltaN-type and TA*-type isoforms may govern the maintenance of epithelial stem cell compartments and regulate the initiation of epithelial stratification from the undifferentiated embryonal ectoderm. Required for limb formation from the apical ectodermal ridge. Activates transcription of the p21 promoter

The "TP63 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about TP63 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets